Peter J Kertes

Is this you? Claim this profile →

No public contact links on file.

Speaking history

EURETINA

23 September 2026 Maastricht, Netherlands “56-week results from the TALON open-label extension, a Phase IIIb/IV study of brolucizumab in a Treat-and-Extend regimen with maximum treatment intervals up to 20 weeks in patients with neovascular age-related macular degeneration”

Sourcing speakers for your event?

Browse the speaker directory →